AU
UK
CA
NZ
IND
US
Last update at 2026-06-03T15:35:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Spire Healthcare Group's (LON:SPI) Returns Have Hit A Wall
Thu 04 Jan 24, 02:02 PMIf EPS Growth Is Important To You, Spire Healthcare Group (LON:SPI) Presents An Opportunity
Mon 02 Oct 23, 01:13 PMWhat Does Spire Healthcare Group plc's (LON:SPI) Share Price Indicate?
Sat 16 Sep 23, 07:56 AMSlowing Rates Of Return At Spire Healthcare Group (LON:SPI) Leave Little Room For Excitement
Fri 28 Jul 23, 01:19 PMEdited Transcript of SPI.L earnings conference call or presentation 8-Sep-22 8:00am GMT
Thu 08 Sep 22, 08:00 AMLondon-listed hospital group Mediclinic accepts £3.7bn offer
Thu 04 Aug 22, 07:51 AMFORM 8.3 - SPIRE HEALTHCARE GROUP PLC
Tue 20 Jul 21, 11:27 AM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 18.60M | 38.30M | 34.60M | 3.90M | -1.90000M |
| Minority interest | - | -0.60000M | -0.60000M | 0.40M | -0.80000M |
| Net income | 16.40M | 25.40M | 27.30M | 8.60M | -8.90000M |
| Selling general administrative | - | - | - | - | - |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 599.10M | 683.60M | 520.60M | 538.40M | 491.20M |
| Reconciled depreciation | - | 112.20M | 103.60M | 97.90M | 97.10M |
| Ebit | 142.90M | 138.20M | 127.60M | 95.40M | 87.00M |
| Ebitda | 262.50M | 250.40M | 231.20M | 187.80M | 177.20M |
| Depreciation and amortization | 119.60M | 112.20M | 103.60M | 92.40M | 90.20M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 142.90M | 137.50M | 126.50M | 95.40M | 87.00M |
| Other operating expenses | 1436.90M | 1373.70M | 1232.50M | 1106.10M | 1026.20M |
| Interest expense | 105.00M | 98.40M | 93.00M | 85.90M | 87.80M |
| Tax provision | - | 12.30M | 6.70M | -4.30000M | 7.00M |
| Interest income | - | 0.70M | 1.40M | 0.00000M | 0.00000M |
| Net interest income | - | -99.20000M | -91.60000M | -91.50000M | -88.80000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.40M | 12.30M | 6.70M | -4.30000M | 7.00M |
| Total revenue | 1579.80M | 1511.20M | 1359.00M | 1198.50M | 1106.20M |
| Total operating expenses | 456.20M | 546.10M | 394.10M | 446.00M | 411.20M |
| Cost of revenue | 980.70M | 827.60M | 838.40M | 660.10M | 615.00M |
| Total other income expense net | -124.30000M | -99.20000M | -91.90000M | -91.50000M | -88.90000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | - | 26.00M | 27.90M | 8.20M | -8.90000M |
| Net income applicable to common shares | - | - | - | 8.60M | -9.70000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2377.10M | 2343.20M | 2288.10M | 2159.80M | 2237.40M |
| Intangible assets | 25.10M | 25.80M | 27.20M | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 28.70M | 29.70M | 27.00M | 1.10M | 104.00M |
| Total liab | 1633.40M | 1597.00M | 1550.30M | 1434.70M | 1532.60M |
| Total stockholder equity | 742.80M | 748.40M | 739.90M | 731.00M | 709.60M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 141.70M | 132.90M | 139.20M | 120.50M | 157.90M |
| Common stock | 4.00M | 4.00M | 4.00M | 4.00M | 4.00M |
| Capital stock | - | 4.00M | 4.00M | 4.00M | 4.00M |
| Retained earnings | -463.20000M | -462.90000M | -472.80000M | -485.70000M | -496.10000M |
| Other liab | - | - | - | 56.20M | 57.70M |
| Good will | 419.70M | 411.60M | 411.10M | 345.80M | 334.80M |
| Other assets | - | - | - | 4.60M | - |
| Cash | 34.70M | 41.20M | 49.60M | 74.20M | 202.60M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 346.80M | 341.70M | 317.60M | 283.40M | 302.10M |
| Current deferred revenue | 8.30M | - | 10.40M | - | - |
| Net debt | 1281.10M | 1238.70M | 1207.40M | 1116.60M | 1062.70M |
| Short term debt | 110.70M | 105.40M | 101.80M | 95.70M | 92.50M |
| Short long term debt | - | 3.60M | 3.40M | 2.90M | 5.70M |
| Short long term debt total | 1315.80M | 1279.90M | 1257.00M | 1190.80M | 1265.30M |
| Other stockholder equity | 825.80M | 829.10M | 829.30M | 1212.70M | 1201.70M |
| Property plant equipment | - | - | - | 1584.40M | 1553.50M |
| Total current assets | 217.60M | 225.30M | 220.60M | 220.00M | 346.80M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 385.20M | 374.80M |
| Short term investments | - | 2.50M | 10.00M | - | - |
| Net receivables | 108.00M | 105.30M | 99.70M | 54.80M | 80.80M |
| Long term debt | - | 363.50M | 361.90M | 321.40M | 421.80M |
| Inventory | 46.20M | 46.60M | 44.30M | 40.60M | 40.20M |
| Accounts payable | 86.10M | 84.90M | 63.90M | 67.20M | 51.70M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 376.20M | 378.20M | 379.40M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3.90M | 16.70M | 10.40M | 9.60M | 2.30M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 2159.50M | 2117.90M | 2067.50M | 1939.80M | 1890.60M |
| Capital lease obligations | - | 912.80M | 891.70M | 866.50M | 837.80M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -99.00000M | -157.20000M | -95.30000M | 0.40M |
| Change to liabilities | - | - | - | 8.20M | 14.30M |
| Total cashflows from investing activities | -90.40000M | -99.00000M | -157.20000M | -95.30000M | -48.30000M |
| Net borrowings | - | 0.00000M | 40.00M | -120.20000M | -14.70000M |
| Total cash from financing activities | -135.40000M | -145.10000M | -82.90000M | -214.70000M | -39.20000M |
| Change to operating activities | - | - | - | -15.90000M | -2.70000M |
| Net income | 16.40M | 25.40M | 27.30M | 3.90M | -1.90000M |
| Change in cash | -6.50000M | -8.40000M | -24.60000M | -128.40000M | 96.30M |
| Begin period cash flow | 41.20M | 49.60M | 74.20M | 202.60M | 106.30M |
| End period cash flow | 34.70M | 41.20M | 49.60M | 74.20M | 202.60M |
| Total cash from operating activities | 219.30M | 235.70M | 215.50M | 181.60M | 183.80M |
| Issuance of capital stock | - | -8.50000M | -0.60000M | 3.10M | - |
| Depreciation | 119.60M | 112.20M | 103.60M | 97.90M | 97.10M |
| Other cashflows from investing activities | - | 10.30M | 0.40M | - | - |
| Dividends paid | 9.20M | 8.50M | 2.00M | 0.30M | 0.10M |
| Change to inventory | 0.40M | -2.30000M | -3.70000M | -0.40000M | -1.90000M |
| Change to account receivables | -5.10000M | -11.00000M | -12.70000M | -6.90000M | 1.70M |
| Sale purchase of stock | -8.70000M | -11.60000M | -3.10000M | - | - |
| Other cashflows from financing activities | -119.70000M | -98.80000M | -117.20000M | 207.50M | -48.30000M |
| Change to netincome | - | - | - | 90.10M | 85.00M |
| Capital expenditures | 76.30M | 112.10M | 84.40M | 87.70M | 69.30M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -5.20000M | -16.00000M | -15.50000M | -15.00000M | 11.40M |
| Stock based compensation | - | 4.70M | 3.70M | 2.30M | 2.80M |
| Other non cash items | 88.50M | 109.40M | 96.40M | 92.50M | 98.10M |
| Free cash flow | 143.00M | 123.60M | 115.50M | 93.90M | 114.50M |
Sector: Healthcare Industry: Medical Care Facilities
| Company | Change (GBX) | Price (GBX) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SPI Spire Healthcare Group Plc |
-0.5 0.23% | 217.00 | 37.06 | 13.91 | 0.38 | 0.78 | 1.18 | 7.70 |
| CVSG CVS Group Plc |
-1.0 0.08% | 1233.00 | 50.87 | 12.08 | 1.18 | 2.69 | 1.52 | 9.51 |
| OHGR One Health Group Plc |
- -% | 251.50 | 24.09 | 18.15 | 1.06 | 2.75 | 0.75 | 10.53 |
| KNB Kanabo Group PLC |
-0.2228 99.02% | 0.0022 | - | - | 1.25 | 0.24 | 0.07 | -2.2141 |
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics in the United Kingdom. The company operates in three segments: Hospitals Business, Vita Health Group, and The Doctors Clinic Group. It provides diagnostics, inpatient, day case, and outpatient care in areas, including orthopedics, gynaecology, cardiology, neurology, oncology, and general surgery; and primary care needs of outpatients, such as GP services, occupational health services, and mental and physical health services. The company also offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. In addition, it provides eye surgery and treatments, family planning, gastroenterology, general medicine, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments. Further, the company offers treatments in the areas of men's health, neurosurgery and neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory medicine, and rheumatology; and scans and investigations, skin treatments, spinal surgery and treatments, sports science, urology, vascular surgery, weight loss, and women's health. Additionally, it provides treatments in the areas of back surgery, breast enlargement, cataract removal surgery, gastric bypass surgery, and prostate surgery; and offers various tests and scans, which include cardiac CT, CT, MRI, ultrasound, and X-ray scans. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.
3 Dorset Rise, London, United Kingdom, EC4Y 8EN
| Name | Title | Year Born |
|---|---|---|
| Mr. Justin J. Ash BA (Hons) | CEO & Exec. Director | NA |
| Mr. Jitesh Himatlal Sodha | CFO & Exec. Director (Leave of Absence) | 1968 |
| Harbant Samra | Group Financial Controller & CFO | NA |
| Mr. John Forrest | Chief Operating Officer | NA |
| Angus Prentice | Interim Head of Investor Relations | NA |
| Ms. Shelley Thomas | Group Human Resurces Director | NA |
| Mr. Mathew Mason | Head of Supply Chain & Purchasing (Central) | NA |
| Mr. Peter Corfield | Chief Commercial Officer | NA |
| Philip Davies | Company Sec. | NA |
| Mr. Justinian Joseph Ash BA (Hons) | CEO & Executive Director | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...